Trends in psychotropic drug use in nursing home residents with dementia and their association with regulatory changes: A routine care data analysis from 2016 to 2023
5 affiliations
- 1Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Medicine for Older People, Amsterdam, The Netherlands
- 2Amsterdam Public Health, Aging and Later Life, Amsterdam, The Netherlands
- 3Amsterdam Public Health, Methodology, Amsterdam, The Netherlands
- 4Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Public and Occupational Health, Amsterdam, The Netherlands
- 5Amsterdam Public Health, Quality of Care, Amsterdam, The Netherlands
Abstract
Introduction: Non-pharmacological interventions are the first-choice treatment for managing neuropsychiatric symptoms in nursing home (NH) residents with dementia, yet psychotropic drugs (PDs) are frequently prescribed despite their limited effectiveness. In the current century, policies in various countries have increasingly emphasized the need for restraint in prescribing PDs, partly through amendments to guidelines and legislation. In the Netherlands, regulatory changes included the 2018 revision of the guideline for challenging behavior, the introduction of the Care and Coercion Act (CCA), and a new Dementia Care Standard in 2020. This study examined the prevalence of PD prescriptions (PDPs) from 2016 to 2023 among residents with dementia in Dutch NHs, and the course of the PDP trend in the context of regulatory changes, using routine care data. Methods: We analyzed routine care data from 11 NH organizations. Quarterly point prevalences were calculated for any PDP and five PD categories separately (antipsychotics, anxiolytics, hypnotics, antidepressants, anti-dementia drugs). We calculated confidence intervals to indicate temporal changes in PDP prevalence and assess the relationship with different reforms. We used interrupted time series (ITS) analysis to explore the association between regulatory changes and the PDP trend. Results: Data from 17,738 residents showed an overall decline in PDP prevalence from 48.3% in 2016 to 42.7% in 2023. Antidepressants and antipsychotics were the most frequently prescribed PDs. Antidepressants showed the largest absolute prevalence decline over time. Anti-dementia drugs showed the greatest relative decline. ITS showed a steeper declining trend after the combined introduction of the CCA and Dementia Care Standard in the second quarter of 2020, compared with the period after the guideline revision in 2018. Discussion: The PDP rate decreased over time but was still substantial. Regulatory changes, including new legislation and (clinical) guidelines, appear to have contributed to a further decline from Q2 2020 onwards. This decline suggests that policy and guideline interventions may meaningfully influence prescribing behavior, offering a promising lever for reducing potentially inappropriate psychotropic use in dementia care. Insight into the appropriateness of prescribing practices is essential to identify areas for further improvement.
Related
- Comparative Effectiveness of Antidepressants and Second-Generation Antipsychotics for Agitation Among Nursing Home Residents with Dementia
- The Impact of a Stepwise Method Involving Family Caregivers in Managing Challenging Behavior and Pain in Nursing Home Residents With Dementia
- Monitoring of palliative care outcomes for nursing home residents with dementia: a secondary exploratory analysis of monthly recurrent deterioration data
- Comparing Effectiveness of Antidepressants for Nursing Home Residents with Dementias and Depressive Symptoms
- Prevalence of frailty and associated factors among aging residents with chronic schizophrenia in Taiwanese psychiatric nursing home: a cross-sectional study.
BibTeX
@article{albers2026trends,
title = {{Trends in psychotropic drug use in nursing home residents with dementia and their association with regulatory changes: A routine care data analysis from 2016 to 2023}},
author = {Charlotte A. W. Albers and Fenne Wouters and Martine C. de Bruijne and Martin Smalbrugge and Karlijn J. Joling},
journal = {PLOS One},
year = {2026},
month = nov,
doi = {10.1371/journal.pone.0361903},
url = {https://doi.org/10.1371/journal.pone.0361903},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Trends in psychotropic drug use in nursing home residents with dementia and their association with regulatory changes: A routine care data analysis from 2016 to 2023
AU - Charlotte A. W. Albers
AU - Fenne Wouters
AU - Martine C. de Bruijne
AU - Martin Smalbrugge
AU - Karlijn J. Joling
PY - 2026
DA - 2026/11/04
JO - PLOS One
DO - 10.1371/journal.pone.0361903
UR - https://doi.org/10.1371/journal.pone.0361903
AB - Introduction: Non-pharmacological interventions are the first-choice treatment for managing neuropsychiatric symptoms in nursing home (NH) residents with dementia, yet psychotropic drugs (PDs) are frequently prescribed despite their limited effectiveness. In the current century, policies in various countries have increasingly emphasized the need for restraint in prescribing PDs, partly through amendments to guidelines and legislation. In the Netherlands, regulatory changes included the 2018 revision of the guideline for challenging behavior, the introduction of the Care and Coercion Act (CCA), and a new Dementia Care Standard in 2020. This study examined the prevalence of PD prescriptions (PDPs) from 2016 to 2023 among residents with dementia in Dutch NHs, and the course of the PDP trend in the context of regulatory changes, using routine care data. Methods: We analyzed routine care data from 11 NH organizations. Quarterly point prevalences were calculated for any PDP and five PD categories separately (antipsychotics, anxiolytics, hypnotics, antidepressants, anti-dementia drugs). We calculated confidence intervals to indicate temporal changes in PDP prevalence and assess the relationship with different reforms. We used interrupted time series (ITS) analysis to explore the association between regulatory changes and the PDP trend. Results: Data from 17,738 residents showed an overall decline in PDP prevalence from 48.3% in 2016 to 42.7% in 2023. Antidepressants and antipsychotics were the most frequently prescribed PDs. Antidepressants showed the largest absolute prevalence decline over time. Anti-dementia drugs showed the greatest relative decline. ITS showed a steeper declining trend after the combined introduction of the CCA and Dementia Care Standard in the second quarter of 2020, compared with the period after the guideline revision in 2018. Discussion: The PDP rate decreased over time but was still substantial. Regulatory changes, including new legislation and (clinical) guidelines, appear to have contributed to a further decline from Q2 2020 onwards. This decline suggests that policy and guideline interventions may meaningfully influence prescribing behavior, offering a promising lever for reducing potentially inappropriate psychotropic use in dementia care. Insight into the appropriateness of prescribing practices is essential to identify areas for further improvement.
SN - 1932-6203
ER -